Scherl, Ellen J <br/><br/>
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.  [electronic resource] 

 -  The American journal of gastroenterology  Jun 2009 
 - 1452-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1572-0241 
<br/><br/><label>Standard No.: </label>10.1038/ajg.2009.83  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anti-Inflammatory Agents, Non-Steroidal--administration & dosage<br/>Colitis, Ulcerative--complications<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Gastrointestinal Hemorrhage--etiology<br/>Humans<br/>Male<br/>Mesalamine--administration & dosage<br/>Middle Aged<br/>Phenylhydrazines--administration & dosage<br/>Prospective Studies<br/>Rectum<br/>Severity of Illness Index<br/>Sigmoidoscopy<br/>Tablets<br/>Treatment Outcome